SGX302 is designed to be a safe alternative for treatment of mild to moderate psoriasis, ideally enabling patients to undergo more treatments to manage their disease while accumulating significantly less risks/toxicities
What is photodynamic light therapy for psoriasis?
Photodynamic light therapy for psoriasis is a two part treatment. First the product is applied topically only where it is needed. That is followed up by a treatment of light to activate the drug.
Photodynamic light therapy in general can use many different kinds of light – UV A, UV B, fluorescent light, lasers, etc. The specific light used depends on the drug molecule and how much energy is needed to activate it.
What is SGX302 Plaque Psoriasis Treatment?
SGX302 is a photodynamic light therapy for psoriasis treatment which uses synthetically manufactured hypericin applied as an ointment and activated with visible fluorescent light. Hypericin is one of the most photoactive compounds known – it is easily activated with relatively low energy light. This makes it ideal for photodynamic therapy because it can be activated with fluorescent light, instead of UV A or UV B light, which are associated with increased cancer risks.
Mechanism of Action
Hypericin, the active ingredient in SGX302, is absorbed by cells in the treated skin and can then be activated by fluorescent light.
When hypericin is activated it creates oxygen radicals that subsequently cause cellular toxicity, killing the targeted cells.
As both the concentration of the drug inside the treated cells and the light intensity increases, there is more destruction of the targeted cells. This may result in clearing of the psoriasis lesion. Because the hypericin is applied topically, it only targets the cells in the lesion, and does not circulate at a high concentration within the body, further reducing toxicity.
Importantly, the mechanism by which the activated hypericin kills cells does NOT involve mutation of the DNA. Therefore, mutagenic risk is minimized. Similarly, use of fluorescent light reduces the carcinogenic risk.
In one of the largest, Phase 3, randomized placebo-controlled trials ever conducted in early stage CTCL, HyBryte™ reduced lesion size in patients in as little as 6 weeks of twice weekly therapy, and this improvement increased the longer plaque psoriasis treatment was continued.
More details on the mechanism of action of hypericin can be found on our HyBryte page and in our Reference Literature webpage.